Sign in
Welcome! Log into your account
Forgot your password? Get helpPrivacy PolicyPassword recovery
Recover your password
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology NewsHomeTopicsArtificial IntelligenceParkinson’s in the Clinic, Insilico enters Phase III, Vertex Acquires Crinetics
Credit: Yuichiro Chino / Moment / Getty Images
Promise hits Parkinson’s disease therapy, as a Phase I/II clinical study has demonstrated the feasibility of transplanting stem-cell-derived dopamine progenitor cells into the brain. In preclinical research, a new platform uses the brain’s fluid transport pathways to effectively deliver AAVs to therapeutic targets in mice. We’ll also cover the accelerating infrastructure moment for AI-driven drug discovery, with billion-dollar investments flowing into end-to-end platforms driven by models and compute, rather than single drug assets. In business, Insilico’s revenue leaps as the company’s AI-developed lead candidate moves to Phase III, while Vertex acquires Crinetics for $10 billion.
Listed below are links to theGENstories referenced in this episode ofTouching Base:
Engineered AAVs Harness Glymphatic System to Reach Brain Targets in Mice
GEN, July 9, 2026
Stem Cell Therapy Shows Promise in First Human Parkinson’s Disease Trial
GEN, July 9, 2026
Pharma Races to Scale AI as Billions Flow into Drug Discovery
By Fay Lin, PhD,GEN Edge, July 6, 2026
StockWatch: Insilico Projects Profit, Revenue Leaps as AI-Developed Lead Candidate Moves to Phase III
By Alex Philippidis,GEN Edge, July 12, 2026
Vertex Eyes Expansion Beyond Cystic Fibrosis with Planned $10B Crinetics Buyout
By Alex Philippidis,GEN Edge, July 7, 2026
Top 20 Drugs Heading for the Patent Cliff, 2026-2029
By Alex Philippidis,GEN Magazine, Nov 1, 2025
Touching Base Podcast
Hosted by Corinna Singleman, PhD
Behind the Breakthroughs
Hosted byJonathan D. Grinstein, PhD
The State of Biologics Testing 2026
Charles River Laboratories andGEN, June 10, 2026
Produced with support from:
Also of Interest
CloudScope Enables Continuous Remote Monitoring of Brain Activity in Freely Moving MiceSmarter Cell Culture Starts with Better MediaRevvity Signs Agreement to Acquire Human Cell DesignTop 10 Contract Development and Manufacturing Organizations 202610 CDMO Up & Comers 2026Harnessing Real-Time DataRelated Media
Data Integrity as the Foundation for AISmall Molecules, Big Expectations: How CDMOs Are Helping Sponsors Navigate Complexity, Speed, Scale-Up, and SustainabilityBeyond the Technology: AI Readiness in Regulated LaboratoriesAACR 2026 Video Update: Cancer Research Edges Toward an AI-Driven EraReporting Live from JPM 2026: Alex Philippidis and Jonathan Grinstein, PhDAI in Protein Design: Hype vs. Reality Explained by David BakerCopyright © 2026 Sage Publications or its affiliates, licensors, or contributors. All rights reserved, including those for text and data mining and training of large language models, artificial intelligence technologies, or similar technologies.
MORE STORIES
